Description: Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery.

Description: TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.

Description: BAX introduces its Dynamo Series smart stretcher, aiming to boost hospital safety and reduce patient transfers.

Description: AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power across medtech stocks.

Description: EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.

Description: TMO ramps up acquisitions and product launches to drive growth, but heavy debt and currency headwinds raise questions for long-term holders.

Description: The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Description: Boston Scientific expects incredibly high growth for its pulsed field ablation (PFA) devices, driven by increased usage of its existing catheters.

Description: ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.

Description: Valencia’s eCoin implantable tibial nerve stimulation (ITNS) system for urge urinary incontinence (UUI) treatment gained FDA approval in 2022.

Description: Medtronic asserted that key markets it targets including PFA and renal denervation represent lucrative opportunities in the near future.

Description: BKD's 4Q25 weighted average occupancy rises to 82.5%, capping a year of gains as resident fees climb.

Description: JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.

Description: Boston Scientific (BSX) reached $95.72 at the closing of the latest trading day, reflecting a -1.97% change compared to its last close.

Description: WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.

Description: The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that work by stimulating the tibial nerve.

Description: ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

Description: Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El

Description: Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).

Description: Boston Scientific (BSX) is drawing fresh attention as investors weigh upbeat analyst commentary, steady demand across key device franchises, and expectations ahead of its February 4 earnings release and projected profit of US$0.78 per share. See our latest analysis for Boston Scientific. At a share price of US$97.64, Boston Scientific has seen a 5.33% 30 day share price return and a 2.91% 1 year total shareholder return, with momentum recently supported by upbeat analyst commentary, product...

Description: In recent days, Boston Scientific has drawn upbeat commentary from Wall Street, with analysts citing strong demand across electrophysiology and structural heart, ongoing trials such as its Global Pulsed Field Ablation program, and a track record of earnings beats ahead of its expected fourth-quarter 2025 results on February 4, 2026. Analysts’ upward earnings estimate revisions and a favorable research-house ranking have reinforced confidence that Boston Scientific’s product pipeline and...

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.

Description: Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.

Description: STE is buoyed by strong Healthcare and AST growth, solid margins and balance sheet strength, even as macro pressures and competition loom.

Description: Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.

Description: AVTR looks worth holding as its broad portfolio, strategic deals and cost savings offset Lab Solutions' weakness for now with AI tools and strong cash flow.

Description: BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.

Description: Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.

Description: Boston Scientific will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit bottom-line growth.

Description: If you are wondering whether Boston Scientific's current share price lines up with its underlying worth, you are not alone. This article focuses on what the numbers may say about value. The stock last closed at US$98.65, with returns of 3.5% over 7 days, 5.1% over 30 days, 4.2% year to date, 2.8% over 1 year, 115.3% over 3 years and 173.6% over 5 years, which many investors look at when weighing growth potential against risk. Recent attention on Boston Scientific has centered on how its...

Description: AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.

Description: PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.

Description: Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Description: Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Description: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Description: The latest trading day saw Boston Scientific (BSX) settling at $97.79, representing a +2.42% change from its previous close.

Description: Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.

Description: OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.

Description: OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.

Description: Many Boston Scientific Corporation ( NYSE:BSX ) insiders ditched their stock over the past year, which may be of...

Description: Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

Description: Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, in San Francisco. Mike Mahoney, chairman and chief executive officer, Jon Monson, executive vice president and chief financial officer, and Ken Stein, M.D., senior vice president and global chief medical officer, will participate in a 40-minute question-and-answer session with the host analyst. The session will begin at approximately 9:00 a.m. PT / 12:00

Description: HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.

Description: CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.

Description: CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.

Description: BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.

Description: Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.

Description: The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Description: Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.

Description: VEEV's strong Q3, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.

Description: Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations U.S. Embolic Protection Device Market U.S. Embolic Protection Device Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States Embolic Protection Device Market Report by Product, Application, Material, End-User, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.United States Embolic Protection Device Market is expected to reach US

Description: OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Description: Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC […]

Description: Boston Scientific's latest narrative update reflects only a subtle recalibration, with the fair value estimate nudging from about $126.48 to $125.86 per share as revenue growth expectations edge higher and the discount rate shifts marginally lower. These small tweaks highlight an ongoing tug of war between bullish views that see durable double digit expansion and growing skepticism that much of that strength is already embedded in the stock. Read on to see how you can stay on top of these...

Description: In recent months, Parnassus Core Equity Fund disclosed a new position in Boston Scientific, while TD Cowen reiterated its positive stance and named the medical device maker its “Best Idea for 2026,” citing products such as Farapulse and Watchman as key growth engines. Together, this institutional backing and upbeat analyst commentary spotlight how Boston Scientific’s early lead in pulsed field ablation and structural heart devices is shaping expectations for its long-term earnings...

Description: Boston Scientific (BSX) has quietly outperformed many medtech peers this year, and with the stock hovering near 96 dollars after a modest pullback, investors are asking whether this long term compounder still offers upside. See our latest analysis for Boston Scientific. That recent dip comes after a strong run, with the share price still up a solid year to date and long term holders enjoying a triple digit total shareholder return over three and five years. This suggests momentum is intact...

Description: ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.

Description: Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.

Description: BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.

Description: Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index surged in the third quarter, driven by investor optimism that grew on expectations of monetary easing, strong consumer demand, and solid corporate earnings. The Fund (Investor […]

Description: Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.

Description: Most readers would already know that Boston Scientific's (NYSE:BSX) stock increased by 4.6% over the past week. Given...

Description: Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen reaffirmed a Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept a $115 price target. The firm went a step further to name Boston Scientific their “Best Idea for 2026.” TD Cowen called Boston Scientific […]

Description: Boston Scientific Corporation (NYSE:BSX) is one of the 14 Best Large Cap Stocks to Invest In Now. On December 17, UBS reiterated its Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept the price target at $140. This update comes even as the shares experienced a drop over the past month. UBS analyst Danielle Antalffy […]

Description: If you are wondering whether Boston Scientific at around $96 a share is still a smart buy, or if most of the upside is already priced in, you are not alone. That is exactly what this breakdown will tackle. The stock has delivered a solid 108.7% return over the last 3 years and 177.9% over 5 years, even if the last month has been slightly softer at -0.9% after a 3.8% bounce in the past week. Recent headlines have focused on Boston Scientific expanding its minimally invasive cardiac and...

Description: PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.

Description: Ecolab closes Ovivo Electronics acquisition, expanding high-tech water solutions for semiconductors and boosting circular water offerings.

Description: DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

Description: BSX expands globally with R&D, AI-driven manufacturing and Emerging Markets, aiming for $1B+ revenues in China in 2025.

Description: Boston Scientific (BSX) reached $94.48 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.

Description: GE HealthCare partners with Indonesia's Health Ministry under SIHREN to deploy CT scanners nationwide, expanding diagnostics across public hospitals.

Description: DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Description: According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...

Description: ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.

Description: Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.

Description: ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.

Description: It might be of some concern to shareholders to see the Boston Scientific Corporation ( NYSE:BSX ) share price down 11...

Description: AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.

Description: CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.

Description: HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.

Description: The latest trading day saw Boston Scientific (BSX) settling at $91.75, representing a -1.02% change from its previous close.

Description: WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.

Description: BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.

Description: HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.

Description: FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.

Description: TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.

Description: CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System.

Description: Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector. With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market. As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.

Description: OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.

Description: Boston Scientific (BSX) is back on investors radar after fresh data underscored how its minimally invasive devices are translating into steady double digit growth in both revenue and earnings. See our latest analysis for Boston Scientific. Despite a choppy stretch, with the latest 1 day share price return at minus 3.77 percent and the 90 day share price return at minus 13.18 percent, Boston Scientific still posts a 1 year total shareholder return of 5.77 percent and a 3 year total shareholder...

Description: In recent commentary, Boston Scientific highlighted expectations for sustained 8–10% annual revenue growth, margin expansion, and double-digit earnings growth powered by its electrophysiology, structural heart, and minimally invasive portfolios, including strong momentum in its FARAPULSE pulsed-field ablation platform and WATCHMAN left atrial appendage closure device. An interesting aspect of this update is the company's commitment to reinvesting 9–10% of revenue into R&D, underpinning a...

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.

Description: Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: We came across a bullish thesis on Boston Scientific Corporation on Value investing subreddit by Infinite_Spinach8839. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $99.02 as of December 2nd. BSX’s trailing and forward P/E were 54.02 and 29.15 respectively according to Yahoo Finance. Boston Scientific Corporation develops, manufactures, and […]

Description: GE HealthCare's seven-year alliance with URMC advances imaging, precision medicine and system-wide monitoring upgrades across UR Medicine.

Description: Wondering if Boston Scientific is still a smart buy at these levels, or if most of the upside has already been priced in? Here is a closer look at what the market might be missing about its value. The stock has cooled off recently, slipping about 3.2% over the last week and 1.1% over the past month, but it is still up 9.3% year to date and 7.9% over the last year, with a 111.0% gain over three years and 187.4% over five years. Those moves have come alongside a steady stream of headlines...

Description: IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.

Description: HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.

Description: GE HealthCare and Mayo Clinic unveil GEMINI-RT, which is likely to blend imaging, AI and monitoring to advance personalized cancer care.

Description: Workday, Inc. (NASDAQ: WDAY), the enterprise AI platform for managing people, money, and agents, has been named a Leader in the 2025 Gartner Magic Quadrant for Financial Planning Software1 for the fourth consecutive year. A complimentary copy of the report is available here.

Description: STE posts solid AST and Healthcare growth, but currency swings and macro pressures pose rising challenges.

Description: Thermo Fisher expands its Bioprocess Design Centers across Asia, boosting biomanufacturing speed, efficiency and regional innovation.

Description: Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.

Description: Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.

Description: Many Boston Scientific Corporation ( NYSE:BSX ) insiders ditched their stock over the past year, which may be of...

Description: ECL's robust product lineup, innovation-driven growth and strong Q2 results underscore its long-term potential despite macroeconomic headwinds.

Description: GE HealthCare launches Allia Moveo with a cable-free C-arm and AI tools, aiming to elevate mobility, access and workflow in interventional care.

Description: Elutia's stock narrative has shifted following analysts' latest reassessment, following the company's recent strategic divestiture. While the fair value estimate remains steady, a slight increase in the discount rate signals cautious sentiment about risk and return. Stay tuned to discover how you can monitor Elutia's evolving outlook and stay informed about future updates. Stay updated as the Fair Value for Elutia shifts by adding it to your watchlist or portfolio. Alternatively, explore our...

Description: Baxter recalls its Life2000 ventilation system over a serious cybersecurity flaw, pulling the device from the market despite no reported injuries.

Description: Henry Schein gains exclusive U.S. rights to Curodont, expanding its vVARDIS partnership and boosting expectations for a Dental business rebound.

Description: Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal

Description: BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.

Description: Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.

Description: GEHC's new SIGNA MRI lineup debuts AI-driven speed, sustainable design and advanced imaging aimed at boosting productivity.

Description: Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.

Description: HSIC gains momentum as Henry Schein One rolls out AI-powered dental workflows unveiled at the Greater New York Dental Meeting.

Description: Boston Scientific stock remains under close watch as the company's fair value target holds steady at $126.48 per share. This reflects analysts' continued confidence following the latest results. While the discount rate saw only a marginal shift, most analysts have reaffirmed or raised their price targets, driven by the company's robust performance and positive outlook. Stay tuned to learn the best ways to monitor the evolving narrative and outlook for Boston Scientific as market conditions...

Description: GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.

Description: According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Boston Scientific has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

Description: Encompass Health teams up with Vanderbilt Health to open a new 40-bed inpatient rehabilitation hospital in Tennessee, targeting a 2028 launch.

Description: GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.

Description: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Description: The Pediatric Interventional Cardiology Market is poised for significant growth, projected to rise from USD 2.42 billion in 2024 to USD 4.34 billion by 2033, exhibiting a 6.68% CAGR. This expansion is driven by the increasing prevalence of congenital heart defects such as VSD, PDA, and ASD in children. The advent of advanced medical devices and the shift towards non-invasive treatments also contribute to market growth. The U.S. stands out as a key player due to rising infant cardiac abnormalitie

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Description: GEHC's $2.3B Intelerad deal aims to accelerate cloud imaging growth, expand outpatient reach and boost its shift toward high-margin SaaS revenue.

Description: The global defibrillator market is forecasted to expand significantly, increasing from US$ 13.74 billion in 2024 to US$ 25.80 billion by 2033, with a steady CAGR of 7.25%. Key drivers include the proliferation of public access defibrillators, expanded ambulance services, and a surge in cardiac ailments. Defibrillators like AEDs and manual devices remain crucial in enhancing survival rates during cardiac arrest emergencies. Top players such as Medtronic, Boston Scientific, and Philips are pivotal

Description: The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

Description: Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Description: DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.

Description: Boston Scientific (BSX) stock has been on the move recently, catching the attention of investors interested in healthcare innovation. With earnings momentum and strong growth trends, market watchers are looking closely at how the company is positioned for the coming months. See our latest analysis for Boston Scientific. Boston Scientific’s latest share price sits at $96.88, with a year-to-date gain of 8.39%. While the past month has seen a pullback, the stock’s three-year total shareholder...

Description: Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Description: Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: VEEV posts a Q3 earnings beat with stronger subscription growth and higher full-year guidance, highlighting continued momentum.

Description: ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Description: Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q2 results, though data security threats remain a key risk.

Description: Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.

Description: Boston Scientific (NYSE:BSX) has had a rough three months with its share price down 7.8%. However, a closer look at its...

Description: Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Description: Medtronic stock jumped and broke out Tuesday on a "clean beat" driven mainly by its pulsed field ablation technology.

Description: Medtronic shares took off after the company posted better financial results than expected, boosted by what management called a “robust” volume of medical procedures. Medtronic sells surgical tools, plus medical devices that treat heart conditions, diabetes, and a range of other conditions, so it benefits when hospitals do more medical procedures. Investors have closely tracked volumes at Medtronic and its peers since the pandemic, which led to delays in many nonessential surgeries.

Description: Butterfly Network unveils Compass AI to streamline POCUS workflows, boosting documentation compliance and unlocking more revenue for health systems.

Description: The consensus price target hints at a 25.3% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Description: MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.

Description: Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.

Description: ECL's new Cooling as a Service platform targets soaring AI data center demand with integrated site-to-chip efficiency upgrades.

Description: The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

Description: Intended for use in structural heart procedures, the cardiac imaging catheter is expected to drive growth for Boston Scientific’s Watchman stroke protection device.

Description: Ever wondered if Boston Scientific is a bargain or if the run-up has left it looking pricey? Let’s dig into what’s driving its value right now. Shares have gained 2.7% in the past week and are up 18.0% over the last year, with a huge 139.0% return in three years. This hints at both solid growth and changing investor sentiment. Much of this momentum is being fueled by Boston Scientific’s recent product launches and its acquisition strategy, which have drawn industry attention and optimism...

Description: Boston Scientific recently reported strong quarterly results, surpassing expectations with 21.4% organic sales growth and raising its full-year 2025 outlook for both revenue and adjusted earnings per share. The company also announced an exclusive distribution agreement for the AcuNav 4D ICE catheter with Siemens Healthineers, aimed at supporting the expansion of its Watchman business and procedural adoption. We'll examine how Boston Scientific's improved financial outlook and new partnership...

Description: Boston Scientific anticipates that assisting in commercialising Siemens Healthineers’ 4D ICE catheter will pay dividends for its Watchman business.

Description: HQY's new agentic AI is likely to provide faster, more intuitive support across channels, aiming to boost member satisfaction.

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: Boston Scientific Corporation (NYSE:BSX) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 23, UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) shares, and increased its price target to $140 from $135. The price target raise comes after Boston Scientific’s quarterly results, which showed organic sales and […]

Description: BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Description: Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.

Description: PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.

Description: Teleflex posts strong Q3 earnings and revenue beats but trims 2025 outlook, sending shares slightly lower.

Description: Rigetti's Q3 loss is narrower than estimates, but revenues decline as government contract delays hit sales and lower the gross margin.

Description: Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Description: Alcon posts mixed Q3 results as earnings top estimates but revenues miss; new product launches fuel optimism.

Description: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...

Description: Novatize, a North American B2B eCommerce agency and system integrator, has been recognized as "B2B Agency of the Year" (Mid/Small System Integrator category) at the B2B eCommerce Industry Awards, presented during B2B eCommerce World Americas held in Scottsdale, Arizona.

Description: DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Description: Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Description: PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.

Description: Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.

Description: Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.

Description: BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.

Description: Boston Scientific's stock has seen a modest increase in its consensus analyst price target, rising slightly from $126.14 to $126.48. This minor upward adjustment reflects a balance between recent optimism around the company's earnings momentum, strategic acquisitions, and longer-term growth strategy. At the same time, there are more cautious views regarding current valuation and potential market risks. To discover how investors and analysts can keep up with the evolving story of Boston...

Description: AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.

Description: DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.

Description: Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.

Description: - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioE

Description: QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.

Description: INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.

Description: PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Description: CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.

Description: BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.

Description: DENTSPLY SIRONA shares drop as Q3 earnings miss estimates and 2025 EPS guidance is cut amid segment weakness.

Description: Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.

Description: McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.

Description: STERIS posts strong Q2 results with earnings and revenue beats, margin expansion, and a raised 2026 EPS outlook.

Description: Boston Scientific (BSX) is in the spotlight after reporting third-quarter financial results that show strong sales growth and operational execution. The company has also expanded its medical device offerings in Peripheral Interventions and Cardiology. See our latest analysis for Boston Scientific. Boston Scientific’s recent momentum in sales and product innovation has kept investors optimistic, helping push the stock to a year-to-date share price return of 10.65%. With a 14.41% total...

Description: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Description: Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.

Description: HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.

Description: Masimo beats third-quarter 2025 earnings and revenue estimates as operating margins and profits improve on lower expenses.

Description: Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.

Description: Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.

Description: Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Description: Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.

Description: Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

Description: Here is how ANIXA BIOSCIENCES INC (ANIX) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.

Description: BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.

Description: Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.

Description: Analysts spotlight GE Aerospace, Cisco, and HSBC for strong gains, strategic shifts, and margin challenges across key growth areas.

Description: Inspire Medical tops third-quarter 2025 estimates as revenue climbs and gross margin improves, with full-year EPS guidance raised.

Description: The market's expansion is bolstered by major players like Cook Medical, Boston Scientific, and Olympus, engaged in ongoing clinical research and product innovation. Challenges include high equipment costs and the scarcity of trained personnel. Major markets include the US, UK, India, and Saudi Arabia. Endobronchial Ultrasound Biopsy Market Endobronchial Ultrasound Biopsy Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Endobronchial Ultrasound Biopsy Market Size and Share Analysis - Growth

Description: Henry Schein's Q3 earnings and revenues top estimates, lifting the stock as the company raised its 2025 outlook on solid business momentum.

Description: Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.

Description: Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]

Description: Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

Description: The US neurology devices market is driven by rising neurological disorders and tech advancements, supported by government R&D funding. Key segments include neurostimulation and neurosurgery devices, with major players like Medtronic and Boston Scientific. Opportunities lie in innovation and strategic collaborations. U.S. Neurology Devices Market U.S. Neurology Devices Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Neurology Devices Market Size, Share, Growth, Trends, Opportu

Description: Over the past year, many Boston Scientific Corporation ( NYSE:BSX ) insiders sold a significant stake in the company...

Description: MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.

Description: DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.

Description: Butterfly Network's Q3 loss widens but revenues top estimates, lifting shares as new AI tools and chip advances drive optimism.

Description: Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

Description: Boston Scientific Corp. (NYSE:BSX) is one of the best stocks to buy according to Citadel LLC. On October 22, Josh Jennings, an analyst at TD Cowen, reiterated his $115 price target and Buy rating on the stock after the company reported strong Q3 2025 results. Jennings said the company’s 15.3% organic growth was the highlight of […]

Description: As Boston Scientific has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Description: Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.

Description: RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.

Description: Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Description: AVTR's Q3 earnings and revenue fell short of estimates, leading the company to cut its full-year 2025 outlook.

Description: DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Description: TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.

Description: OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

Description: Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.

Description: Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Description: Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.

Description: BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.

Description: The AI rally has many investors wondering where to turn in anticipation of its end. The medical-device maker is one solid option.

Description: ​Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $132. ​The rating comes after the company, on October 22, released results for its fiscal […]

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.

Description: GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.

Description: Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.

Description: Boston Scientific’s third quarter saw a positive market reaction, reflecting operational execution across multiple business units. Management attributed the strong results to broad-based growth, especially in electrophysiology and the WATCHMAN left atrial appendage closure device, which CEO Michael Mahoney called “a gem for Boston Scientific.” The company also noted resilient demand in the U.S. and Asia Pacific, with double-digit growth in Japan and China. Mahoney emphasized that growth was driv

Description: If you are trying to figure out what to do with Boston Scientific stock right now, you are not alone. It is one of those names that investors keep coming back to, especially after a remarkable run in recent years. Just think about it: the stock has climbed an impressive 19.4% in the past year and a staggering 187.3% over five years. Even more, the year-to-date gain of 13.0% and a steady 2.8% in the last 30 days suggest this momentum may have staying power. Behind these moves is a string of...

Description: What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Description: The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory diseases, advancements in nebulizer technology, and an increased focus on home healthcare solutions. Nebulizers offer effective inhalation therapy for conditions like asthma, COPD, and cystic fibrosis. Technological improvements such as smart connectivity and portable designs enhance user convenience,

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.

Description: The consensus price target hints at a 25.6% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Description: GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.

Description: The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card

Description: Boston Scientific stock is under fresh scrutiny as analysts adjust their price targets upward. The consensus figure is now $126.14, up from $124.53. This incremental rise reflects optimism fueled by strong quarterly results and revised guidance, balanced against an evolving competitive landscape. Read on to discover how you can stay ahead of future updates as the narrative around Boston Scientific continues to develop. What Wall Street Has Been Saying Analyst sentiment on Boston Scientific...

Description: Boston Scientific reported third-quarter 2025 results that exceeded analyst expectations, with revenue rising to US$5.07 billion and net income increasing to US$755 million, supported by strong performance across multiple segments and regions. The company raised its financial guidance for the fourth quarter and full year 2025, driven by robust growth in its cardiovascular segment, ongoing product innovation like the FARAPULSE system, and the recent acquisition of Nalu Medical expanding its...

Description: Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.

Description: West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.

Description: Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Description: Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Description: Companies in The News Are: BSX, ISRG, BCS, CB

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Boston Scientific (BSX) delivered standout earnings growth, with profits up 18.5% per year over the last five years and a strong 37% gain in the most recent year. Net profit margins rose to 13.5% from 12% previously. Forward-looking guidance points to annual earnings growth of 16.6%, ahead of the US market average, and revenue growth is forecast at 9.6% per year. With the share price trading below analyst targets, investors are likely to view these results as continued evidence of...

Description: Boston Scientific stock jumped Wednesday after its Watchman and electrophysiology franchises helped drive a third-quarter beat.

Description: Boston Scientific Corp (BSX) reports robust operational and organic sales growth, driven by key segments and strategic expansions, despite regional challenges.

Description: Boston achieved a 22.4% growth in its cardiovascular business in Q3, continuing the segment’s growth trend in 2025 due to the ongoing adoption of its Farapulse PFA system.

Description: GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Description: Shares of medical device company Boston Scientific (NYSE:BSX) jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised its full-year financial outlook.

Description: Boston Scientific (BSX) raised its full-year guidance on Wednesday as the medical device supplier's

Description: (Updates with latest stock movement in the headline and first paragraph.) Boston Scientific (BSX)

Description: Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.

Description: Strong sales growth in the company’s electrophysiology unit comes amid a market fight between some of the medtech industry’s largest players.

Description: Boston Scientific (BSX) delivered earnings and revenue surprises of +5.63% and +1.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The main US stock measures were trending lower in Wednesday's premarket activity as President Donald

Description: Medical device company Boston Scientific (NYSE:BSX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.

Description: The medical device company recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.

Description: The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share. The medical device manufacturer posted revenue of $5.07 billion in the period, which also beat Street forecasts.

Description: Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted3 EPS of $0.75 for

Description: The U.S. government shutdown continues, but investors won't be completely starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.

Description: Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen reaffirmed its Buy rating and $115 price target on the company on October 10. According to the firm, the visit strengthened its belief in Boston Scientific’s outlook, which it […]

Description: The U.S. government shutdown continues, but investors won't be completely starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Medical device company Boston Scientific (NYSE:BSX) will be announcing earnings results this Wednesday morning. Here’s what to expect.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Here is how Boston Scientific (BSX) and Amarin (AMRN) have performed compared to their sector so far this year.

Description: Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

Description: The U.S. government shutdown is set to drag into another week, but that doesn’t mean investors will be starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: As investors enters shutdown week three, a US-China trade war, credit gesticulation, and an incoming oil glut are weighing on the market.

Description: Boston Scientific (BSX) has seen its stock gradually climb in recent weeks, supported by consistent revenue and net income growth. Investors are likely watching the pace of these gains to gauge whether the company’s momentum can be sustained. See our latest analysis for Boston Scientific. After an impressive start to the year, Boston Scientific’s share price now sits at $99.24, posting an 11% return year-to-date. Recent momentum has been steady, supporting a solid 1-year total shareholder...

Description: The U.S. government shutdown is set to drag into another week, but that doesn’t mean investors will be starved for economic data. Next Friday brings a (delayed) look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Nalu’s PNS system complements Boston’s existing neuromodulation portfolio, which includes its WaveWriter Alpha SCS system for chronic spinal pain.

Description: Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: Intuitive Surgical enters Q3 earnings season on strong momentum, backed by robust procedure growth and da Vinci 5 adoption. However, tariff risks and global CapEx constraints remain challenges.

Description: Nalu’s implantable neurostimulation system delivers electrical impulses to treat chronic pain originating from the peripheral nerves.

Description: Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.